The Latest Cardiac and Vascular News
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes
NEW YORK, April 20, 2026 /PRNewswire/ — Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by…
Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and […]
MADRID, April 17, 2026 /PRNewswire/ — Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac…
SOUTHLAKE, Texas & YOKNEAM, Israel–(BUSINESS WIRE)– #LVO–FDA clears TIGERTRIEVER™ 25 adjustable thrombectomy device by Rapid Medical; first U.S. cases show first-pass success in ischemic stroke.
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs. insulin glargine, showing the…
Among Nation’s First Programs to Offer the Innovative Procedure to Treat Valve Deformities in Children MIAMI, April 15, 2026 /PRNewswire/ — The cardiovascular surgery team at Nicklaus Children’s Hospital’s Heart Institute has successfully performed the first partial heart transplant in…
NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced a multi-year agreement with Specialized Medical. Under this partnership, AccurKardia’s FDA-cleared Class II software as a medical device (SaMD), AccurECG™ 2.0, is actively powering Specialized Medical’s state-of-the-art cardiac monitoring operations, which currently serve more than 20 clinics, medical practices, and hospitals across four states. Specialized
SAN FRANCISCO–(BUSINESS WIRE)–Bunkerhill Health, an agentic AI company building healthcare’s system of action, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a new national billing code and associated payment under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC) on chest CT scans, effective April 1, 2026. The company also received U.S. Food and Drug Adm
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online: A webcast of the call will be available on the Investor Relations section of the Company’s website at www.amarincorp.com.Access to the replay:Via telephone: Dial in within the United States: 877-481-4010International dial in: 919-882-2331Replay Code: 53836 Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company’s website at www.amarincorp.com, beginning shortly after the end of the live call and available until 10/29/26. About AmarinAmarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD. Availability of Other Information About Amarin Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact InformationMedia Inquiries: Tegan Berry Amarin Corporation plc PR@amarincorp.com Investor Inquiries:Devin Sullivan & Conor RodriguezThe Equity Group on Behalf of Amarin dsullivan@theequitygroup.com or crodriguez@theequitygroup.com Investor.relations@amarincorp.com
